Content about Diabetes

NEW YORK — Research published in the latest issue of Archives of Dermatology, a JAMA network publication, found that an inflammatory skin disease is an independent risk for Type 2 diabetes.

LOUISVILLE, Ky., and PRINCETON, N.J. — A healthcare company and a drug maker have entered a one-year research partnership to explore diabetes treatment and care.

Humana and Novo Nordisk said its researchers will identify opportunities to change how patients might be treated to improve quality and outcomes for the millions of people who battle diabetes. Humana is working through its research affiliate, Competitive Health Analytics, on this partnership, Humana noted.

DEERFIELD, Ill. — A new Walgreens study released Thursday found that a pharmacist-led training and counseling program for patients receiving an injectable diabetes medication improved medication adherence by 24%.

PHILADELPHIA — When one of Amylin Pharmaceuticals' diabetes drugs is used with mealtime insulin, both Type 1 and Type 2 diabetes patients maintain blood sugar in the normal glucose range on a daily basis, according to two analyses presented at the 72nd Scientific Sessions of the American Diabetes Association.

FRANKLIN LAKES, N.J. — A diabetes research organization and a medical technology company have extended their partnership.

The Juvenile Diabetes Research Foundation and medical supply manufacturer BD — which previously collaborated to enhance the use of insulin pumps in patients with Type 1 diabetes — said they will accelerate the development of BD's proprietary glucose-sensing technology, which has shown promise in providing very accurate and reliable continuous glucose information.

HOUSTON — Novo Nordisk is starting an organization in Houston designed to provide assistance to local diabetes education programs, the Danish drug maker said Tuesday.

The company announced that it was accepting applications from local organizations for funding from Novo Nordisk Community Care Houston, one of more than 20 Novo Nordisk Community Care programs started in 2011 that provide funding to local groups. The drug maker is investing $80,000 on the Houston initiative.

PHILADELPHIA — An integrated wellness team approach to diabetes care can help patients not only improve their condition, but also lower their prescription costs, according to new research presented at the American Association of Clinical Endocrinologists' 21st annual Scientific and Clinical Congress in Philadelphia.

PHILADELPHIA — An interactive user-friendly program that breaks down diabetes management into four goals to help people with Type 2 diabetes better manage their disease has made its debut.

PRINCETON, N.J. — The Food and Drug Administration has approved a treatment for Type 1 diabetes in children ages 2 to 5 years.

Drug maker Novo Nordisk announced Tuesday the additional approval of Levemir (insulin detemir [rDNA origin]). The insulin already was approved for Type 1 diabetes in older children and adults and Type 2 diabetes in adults, and the drug maker said the new FDA approval made Levemir the only basal insulin analog for use in the 2 to 5 year age group.

BRIDGEWATER, N.J. — Amneal Pharmaceuticals is adding blackberry flavoring to a generic diabetes drug following feedback from customers, the company said Wednesday.

Amneal announced the changes to its metformin hydrochloride immediate-release tablets in the 500-mg, 850-mg and 1,000-mg strengths, designed to cover up the smell of metformin.

CHICAGO — MinuteClinic, which is owned by CVS Caremark, announced on Monday that it has joined a coalition of organizations dedicated to raising diabetes awareness among families on Chicago's South Side.

The coalition is working with Perspectives Charter School Calumet Campus to educate, screen, diagnose and, if needed, provide follow-up care to any student diagnosed with pre-diabetes or diabetes.

DEERFIELD, Ill. — The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.

Takeda announced that the FDA issued a complete response letter for its regulatory applications for the Type 2 diabetes drug alogliptin and a combination pill that includes alogliptin and pioglitazone, the active ingredient in the drug Actos.